AbbVie, Calibr to develop universal CAR T therapies

AbbVie Inc. (NYSE:ABBV) and the California Institute for Biomedical Research (La Jolla, Calif.) partnered to develop universal CAR T therapies using the non-profit's switchable CAR T technology to treat

Read the full 291 word article

User Sign In